Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2006

Open Access 01-12-2006 | Methodology

Elevated serum triglycerides is the strongest single indicator for the presence of metabolic syndrome in patients with type 2 diabetes

Authors: Maria Kompoti, Anargiros Mariolis, Alevizos Alevizos, Ioannis Kyriazis, Ioannis Protopsaltis, Eleni Dimou, Ioannis Lentzas, Dimitrios Levisianou, Afroditi Gova, Andreas Melidonis

Published in: Cardiovascular Diabetology | Issue 1/2006

Login to get access

Abstract

Background

Patients with diabetes already fulfill one diagnostic criterion for MS according to the existing classifications. Our aim was to identify one single clinical parameter, which could effectively predict the presence of MS in patients with type 2 diabetes.

Methods

We studied all patients with type 2 diabetes who attended our Diabetes Outpatient Clinic during a three-month period. Waist circumference, blood pressure and serum lipids were measured. Establishment of MS diagnosis was based a) on National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria and b) on International Diabetes Federation (IDF) criteria. Receiver operating characteristic (ROC) analysis was applied in order to identify the clinical parameter with the highest predictive capability for MS. Among the 500 participating patients (231 males, 269 females), MS was diagnosed in 364 patients (72.8%) according to the NCEP ATP III criteria and in 408 patients (81.6%) according to the IDF criteria.

Results

For the NCEP ATP III classification, serum triglycerides (in the overall population), waist and HDL (in female population) demonstrated the highest predictive capability for MS (AUCs:0.786, 0.805 and 0.801, respectively). For the IDF classification, no single parameter reached an AUC > 0.800 in the overall population. In females, HDL displayed a satisfactory predictive capability for MS with an AUC which was significantly higher than the one in males (0.785 vs. 0.676, respectively, p < 0.05).

Conclusion

Elevated serum triglycerides strongly indicate the presence of MS in patients with type 2 diabetes. In female patients with type 2 diabetes, central obesity was the second stronger predictor of MS besides hypertriglyceridemia.
Literature
1.
go back to reference Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, taskinen MR, Groop L: Cardiovascular mortality and mortality associated with the metabolic syndrome. Diabetes Care. 2001, 24: 683-689. 10.2337/diacare.24.4.683.CrossRefPubMed Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, taskinen MR, Groop L: Cardiovascular mortality and mortality associated with the metabolic syndrome. Diabetes Care. 2001, 24: 683-689. 10.2337/diacare.24.4.683.CrossRefPubMed
2.
go back to reference Haffner SM: The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol. 2006, 97 (2A): 3A-11A. 10.1016/j.amjcard.2005.11.010.CrossRefPubMed Haffner SM: The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol. 2006, 97 (2A): 3A-11A. 10.1016/j.amjcard.2005.11.010.CrossRefPubMed
3.
go back to reference Lorenzo C, Williams K, Hunt KJ, Haffner SM: Trend in the prevalence of the metabolic syndrome and its impact on cardiovascular disease incidence: the San Antonio Heart Study. Diabetes Care. 2006, 29 (3): 625-30. 10.2337/diacare.29.03.06.dc05-1755.CrossRefPubMed Lorenzo C, Williams K, Hunt KJ, Haffner SM: Trend in the prevalence of the metabolic syndrome and its impact on cardiovascular disease incidence: the San Antonio Heart Study. Diabetes Care. 2006, 29 (3): 625-30. 10.2337/diacare.29.03.06.dc05-1755.CrossRefPubMed
4.
go back to reference Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001, 288: 2486-2497. 10.1001/jama.285.19.2486. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001, 288: 2486-2497. 10.1001/jama.285.19.2486.
5.
go back to reference Alberti G: Introduction to the metabolic syndrome. Eur Heart J. 2005, 7 (Suppl D): 3-5.CrossRef Alberti G: Introduction to the metabolic syndrome. Eur Heart J. 2005, 7 (Suppl D): 3-5.CrossRef
6.
go back to reference Alexander CM, Landsman PB, Teutsch SM, Haffner SM: NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003, 52: 1210-1214. 10.2337/diabetes.52.5.1210.CrossRefPubMed Alexander CM, Landsman PB, Teutsch SM, Haffner SM: NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes. 2003, 52: 1210-1214. 10.2337/diabetes.52.5.1210.CrossRefPubMed
7.
go back to reference Hanley JA, McNeil BJ: The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982, 143: 29-36.CrossRefPubMed Hanley JA, McNeil BJ: The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982, 143: 29-36.CrossRefPubMed
8.
go back to reference Hanley JA, McNeil BJ: A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983, 148: 839-843.CrossRefPubMed Hanley JA, McNeil BJ: A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983, 148: 839-843.CrossRefPubMed
9.
go back to reference Sackett DL, Hayes RB, Guyatt GH, Tugwell P: The interpretation of diagnostic data (Ch. 4). Clinical Epidemiology: A Basic Science for Clinical Medicine. 1991, Little, Brown and Company, Boston MA, 69-152. 2 Sackett DL, Hayes RB, Guyatt GH, Tugwell P: The interpretation of diagnostic data (Ch. 4). Clinical Epidemiology: A Basic Science for Clinical Medicine. 1991, Little, Brown and Company, Boston MA, 69-152. 2
10.
go back to reference Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial (MRFIT). Diabetes Care. 1993, 16: 434-444. 10.2337/diacare.16.2.434.CrossRefPubMed Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial (MRFIT). Diabetes Care. 1993, 16: 434-444. 10.2337/diacare.16.2.434.CrossRefPubMed
11.
go back to reference World Health Organization: Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Part I: Diagnosis and Classification of Diabetes Mellitus. 1999, Geneva, World Health Org World Health Organization: Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Part I: Diagnosis and Classification of Diabetes Mellitus. 1999, Geneva, World Health Org
12.
go back to reference Ford ES, Giles WH: A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care. 2003, 52: 2740-2747.CrossRef Ford ES, Giles WH: A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care. 2003, 52: 2740-2747.CrossRef
13.
go back to reference Meigs JB, Wilson PWF, Nathan DM, D'Agostino RB, Williams K, Haffner SM: Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring studies. Diabetes. 2003, 52: 2160-2167. 10.2337/diabetes.52.8.2160.CrossRefPubMed Meigs JB, Wilson PWF, Nathan DM, D'Agostino RB, Williams K, Haffner SM: Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring studies. Diabetes. 2003, 52: 2160-2167. 10.2337/diabetes.52.8.2160.CrossRefPubMed
14.
go back to reference Bruno G, Merletti F, Biggeri A, Bargero G, Ferrero S, Runzo C, Prina Cerai S, Pagano G, Cavallo-Perin P: Casale Monferrato Study. Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diabetes Care. 2004, 27: 2689-2694. 10.2337/diacare.27.11.2689.CrossRefPubMed Bruno G, Merletti F, Biggeri A, Bargero G, Ferrero S, Runzo C, Prina Cerai S, Pagano G, Cavallo-Perin P: Casale Monferrato Study. Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diabetes Care. 2004, 27: 2689-2694. 10.2337/diacare.27.11.2689.CrossRefPubMed
15.
go back to reference Bonora E, Targher G, Formentini G, Calcaterra F, Lombardi S, Marini P, Zenari L, Saggiani F, Poli M, Perbellini S, Raffaelli A, Gemma L, Santi L, Bonadonna RC, Muggeo M: The metabolic syndrome is an independent predictor of cardiovascular disease in type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diabet Med. 2004, 21: 52-58. 10.1046/j.1464-5491.2003.01068.x.CrossRefPubMed Bonora E, Targher G, Formentini G, Calcaterra F, Lombardi S, Marini P, Zenari L, Saggiani F, Poli M, Perbellini S, Raffaelli A, Gemma L, Santi L, Bonadonna RC, Muggeo M: The metabolic syndrome is an independent predictor of cardiovascular disease in type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. Diabet Med. 2004, 21: 52-58. 10.1046/j.1464-5491.2003.01068.x.CrossRefPubMed
Metadata
Title
Elevated serum triglycerides is the strongest single indicator for the presence of metabolic syndrome in patients with type 2 diabetes
Authors
Maria Kompoti
Anargiros Mariolis
Alevizos Alevizos
Ioannis Kyriazis
Ioannis Protopsaltis
Eleni Dimou
Ioannis Lentzas
Dimitrios Levisianou
Afroditi Gova
Andreas Melidonis
Publication date
01-12-2006
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2006
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-5-21

Other articles of this Issue 1/2006

Cardiovascular Diabetology 1/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.